Y Intercept Hong Kong Ltd Has $2.96 Million Holdings in Waters Corporation $WAT

Y Intercept Hong Kong Ltd lifted its holdings in shares of Waters Corporation (NYSE:WAT) by 271.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,938 shares of the medical instruments supplier’s stock after purchasing an additional 7,263 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Waters were worth $2,960,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in WAT. Pinnacle Associates Ltd. increased its stake in Waters by 0.3% during the 4th quarter. Pinnacle Associates Ltd. now owns 7,608 shares of the medical instruments supplier’s stock worth $2,890,000 after acquiring an additional 26 shares during the period. Exencial Wealth Advisors LLC grew its holdings in shares of Waters by 1.7% during the 4th quarter. Exencial Wealth Advisors LLC now owns 1,681 shares of the medical instruments supplier’s stock worth $638,000 after purchasing an additional 28 shares in the last quarter. Rosenberg Matthew Hamilton grew its holdings in shares of Waters by 8.8% during the 4th quarter. Rosenberg Matthew Hamilton now owns 359 shares of the medical instruments supplier’s stock worth $136,000 after purchasing an additional 29 shares in the last quarter. Clearstead Advisors LLC increased its position in shares of Waters by 5.1% in the fourth quarter. Clearstead Advisors LLC now owns 616 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 30 shares during the period. Finally, Integrated Wealth Concepts LLC raised its stake in Waters by 2.9% in the first quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after purchasing an additional 30 shares in the last quarter. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Piper Sandler assumed coverage on shares of Waters in a research note on Thursday, June 11th. They set a “neutral” rating and a $400.00 price objective on the stock. HSBC increased their price target on shares of Waters from $415.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. TD Cowen lifted their price objective on shares of Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Barclays upped their target price on Waters from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Evercore reaffirmed an “outperform” rating and issued a $410.00 target price on shares of Waters in a report on Monday. Four analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $399.84.

Waters Price Performance

Shares of NYSE:WAT opened at $374.94 on Wednesday. Waters Corporation has a one year low of $275.05 and a one year high of $414.15. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The company has a market cap of $36.82 billion, a price-to-earnings ratio of 47.64, a PEG ratio of 2.29 and a beta of 1.20. The firm has a 50 day simple moving average of $354.18 and a 200 day simple moving average of $346.74.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the business earned $2.25 earnings per share. The company’s revenue for the quarter was up 91.4% compared to the same quarter last year. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Research analysts predict that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.